An observational study in Psoriasis, sponsored by Bristol-Myers Squibb. Recruiting at 48 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-18.
Sponsored by Bristol-Myers Squibb · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Psoriasis by Bristol-Myers Squibb — 9 open to participants now, 14 under way, 4 of them phase 3. Psoriasis · Bristol-Myers Squibb.
Among the 42 studies in Psoriasis by Bristol-Myers Squibb, this one is the 10th largest by planned enrollment of the 14 observational ones that give a count, is one of 7 that started in 2025, is one of 14 observational ones, reaches primary completion later than 5 of the 13 other live ones, and was the 35th registered.
2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.
Browse Psoriasis studies →9 of the 42 studies in Psoriasis by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in United States, Argentina, Belgium and 13 more countries
Ages 12–17
Bristol-Myers Squibb · Sites in United States, Argentina, Australia and 22 more countries
Ages 40+
Bristol-Myers Squibb · Sites in United States
Women only · Healthy volunteers
Bristol-Myers Squibb · Sites in Korea, Republic of
Ages 19+
Bristol-Myers Squibb · Sites in Japan
Ages 18+
By country, each count listing its studies:
Of the 175 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 67 (38%) stop at 75 or younger; 25 take children under 18; 42 take healthy volunteers.
This study: 18 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 6 · Phase 3 9 · Phase 4 3
First in 1995; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 350 is above the median of 200 across 408 observational studies indexed under Psoriasis.
Median enrollment 131 across the 28 interventional studies, 528 across the 14 observational. Of the 28 that completed or were terminated, 10 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
3 of the studies in Psoriasis by Bristol-Myers Squibb that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06710470Bristol-Myers SquibbA Study on the Safety of Deucravacitinib Exposure in Pregnant Women and Their Offspring | 2027-01-31 |
| NCT06512337Bristol-Myers SquibbA Observational Study to Evaluate Deucravacitinib in Patients With Moderate Plaque Psoriasis in China | 2027-03-11 |
| NCT07256015Bristol-Myers SquibbDeucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy | 2027-07-05 |
Add all 3 to your calendar (.ics) → With an account.
Among the 42 studies in Psoriasis by Bristol-Myers Squibb, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the real-world effectiveness of deucravacitinib treatment in adults diagnosed with moderate-to-severe plaque psoriasis
Adult patients who have been diagnosed with moderate-to-severe plaque psoriasis and who intend to start deucravacitinib treatment in France
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Deucravacitinib
As prescribed by treating clinician
Physician's Global Assessment (PGA) 0/1 response
Time frame: Baseline and at months 4, 12, 18 (optional), and 24
Dermatology Life Quality Index (DLQI) 0/1 response
Time frame: Baseline and at months 4, 12, 18 (optional), and 24
Time from date of treatment initiation to date of discontinuation
Time frame: Up to 24 months
Change in percentage involved Body Surface Area (BSA) from start of deucravacitinib treatment
Time frame: Baseline and at months 4, 12, 18 (optional), and 24
Change in patient reported symptom burden as assed by the 100-point Visual Analog Scale (VAS) - Itch
Time frame: Baseline and months 1, 4, 12, 18 (optional) and 24
Change in patient reported symptom burden as assed by the 100-point Visual Analog Scale (VAS) - Skin pain
Time frame: Baseline and months 1, 4, 12, 18 (optional) and 24
Change in patient reported symptom burden as assed by the 100-point Visual Analog Scale (VAS)] - Fatigue
Time frame: Baseline and months 1, 4, 12, 18 (optional) and 24
Physician's Global Assessment (PGA) score change from start of deucravacitinib treatment to follow-up
Time frame: Baseline and at months 4, 12, 18 (optional), and 24
Dermatology Life Quality Index (DLQI) score of ≤5
Time frame: Baseline and at months 1, 4, 12 18 (optional) and 24
Body Surface Area (BSA) of ≤ 3%
Time frame: Baseline and at months 4, 12, 18 (optional), and 24
Body Surface Area (BSA) of ≤ 1%
Time frame: Baseline and at months 4, 12, 18 (optional), and 24
Reasons for deucravacitinib treatment discontinuation
Time frame: Up to 24 months
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Plan to share: No
Started Jan 2025 (actual). Primary completion is estimated for Apr 2028, 39 months after the start.
Of 81 industry-sponsored observational studies under Psoriasis, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 74. This study's planned 39 months is close to that.
Counting every sponsor, half of 174 studies reached it within 37 months; a quarter within 23 and three quarters within 93.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.